| NCT03929666 | Jazz Pharmaceuticals | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | 2019-08-29 | PHASE2 |
| NCT07494448 | MedSIR | HER 2 Positive Advanced Breast Cancer|Breast Cancer | 2026-07-01 | PHASE1|PHASE2 |
| NCT06043427 | Canadian Cancer Trials Group|Jazz Pharmaceuticals | Gastroesophageal Adenocarcinoma | 2024-04-16 | PHASE2 |
| NCT07477444 | Universitaire Ziekenhuizen KU Leuven | Gastroesophageal Cancer | 2026-06-01 | PHASE1|PHASE2 |
| NCT07405476 | Emory University|National Cancer Institute (NCI) | Colon Carcinoma|Colorectal Carcinoma|Rectal Carcinoma|Stage I Colon Cancer AJCC v8|Stage I Colorectal Cancer AJCC v8|Stage I Rectal Cancer AJCC v8|Stage II Colon Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage II Rectal Cancer AJCC v8|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8 | 2026-04-07 | PHASE2 |
| NCT07273981 | Xijing Hospital | Gastric+Gastroesophageal Junction Adenocarcinoma | 2026-01-01 | PHASE2 |
| NCT05027139 | Jazz Pharmaceuticals|ALX Oncology Inc. | HER2-expressing Cancers | 2021-09-15 | PHASE1|PHASE2 |
| NCT05152147 | Jazz Pharmaceuticals|BeOne Medicines LTD|BeOne Pharmaceutical Co., Ltd. | Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma | 2021-12-02 | PHASE3 |
| NCT07102381 | Jazz Pharmaceuticals|Jazz Pharmaceuticals Ireland Limited | HER2-positive Breast Cancer|Breast Cancer | 2025-09-24 | PHASE2 |
| NCT04224272 | Jazz Pharmaceuticals | HER2&addition;+HR&addition; Breast Cancer | 2020-06-10 | PHASE2 |
| NCT04164199 | BeOne Medicines | Advanced Malignancies | 2019-12-19 | PHASE3 |
| NCT04466891 | Jazz Pharmaceuticals|BeiGene|Jazz Pharmaceuticals Ireland Limited|BeOne Medicines LTD | HER2-amplified Biliary Tract Cancers | 2020-10-01 | PHASE2 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT07176312 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Jazz Pharmaceuticals | Gastroesophageal Adenocarcinoma|First Line Therapy|HER2 &addition; Gastric Cancer|PDL-1|Metastases | 2026-01-16 | PHASE2 |
| NCT06324357 | Boehringer Ingelheim | Metastatic Breast Cancer|Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma|Colorectal Cancer | 2024-06-03 | PHASE1|PHASE2 |
| NCT05615818 | UNICANCER|Cancer Research UK & UCL Cancer Trials Centre|Belgian Group of Digestive Oncology|National Cancer Institute, France|Cancer Research UK|Taiho Oncology, Inc.|Servier|Zymeworks BC Inc.|Accord Healthcare, Inc.|Pierre Fabre Medicament | Biliary Tract Neoplasms | 2024-07-18 | PHASE3 |
| NCT07243938 | Tao Zhang | Locally Advanced Rectal Cancer (LARC)|Locally Advanced Gastric+Gastroesophageal Junction Adenocarcinoma|Metastatic Colorectal Cancer (mCRC)|Neoadjuvant Therapy | 2026-01-15 | PHASE2 |
| NCT07296705 | Fujian Medical University Union Hospital|BeiGene | Muscle Invasive Bladder Cancer (MIBC) | 2025-10-25 | PHASE2 |
| NCT02892123 | Jazz Pharmaceuticals | HER2-expressing Cancers | 2016-09-30 | PHASE1 |
| NCT05868226 | QuantumLeap Healthcare Collaborative | HER2-positive Breast Cancer|Metastatic Cancer|Metastatic Breast Cancer|Metastatic|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2-negative Breast Cancer|Triple Negative Breast Cancer|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Solid Tumor|Solid Tumor, Adult|Solid Carcinoma|HER2 Low Breast Cancer|HER2 Low Breast Carcinoma|ER Positive Breast Cancer|PR-positive Breast Cancer | 2023-02-15 | PHASE1 |
| NCT04578444 | Jazz Pharmaceuticals | HER2-Positive Advanced Biliary Tract Cancer | | |
| NCT07290985 | American Association for Cancer Research|Jazz Pharmaceuticals|BeOne Medicines|Astellas Pharma Global Development, Inc.|Natera, Inc.|Roche Diagnostic Ltd. | Gastroesophageal Adenocarcinoma | 2026-05-01 | PHASE2 |
| NCT06695845 | Jazz Pharmaceuticals|Jazz Pharmaceuticals Ireland Limited | Breast Cancer|Gastric Cancer|Esophageal Cancer|Gastroesophageal Cancer|Colorectal Cancer|Endometrial Cancer|Non-small Cell Lung Cancer|Ovarian Cancer|Urothelial Carcinoma|Salivary Gland Cancer|Pancreatic Cancer|HER-2 Protein Overexpression | 2025-01-14 | PHASE2 |
| NCT06282575 | Jazz Pharmaceuticals | Biliary Tract Cancer | 2024-07-19 | PHASE3 |
| NCT05035836 | M.D. Anderson Cancer Center|Zymeworks BC Inc. | Breast Cancer|HER2-positive | 2021-11-16 | PHASE2 |
| NCT04513665 | Memorial Sloan Kettering Cancer Center|Zymeworks BC Inc. | Endometrial Cancer|Carcinosarcoma | 2020-08-12 | PHASE2 |